{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:31:34Z","timestamp":1791297094439,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,10,23]],"date-time":"2009-10-23T00:00:00Z","timestamp":1256256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2010,2]]},"abstract":"<jats:sec><jats:label\/><jats:p> <jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Dry cough is a common and well\u2010documented side\u2010effect of angiotensin\u2010converting enzyme inhibitor (ACEi) treatment.<\/jats:p><jats:p>\u2022\u2003The recommended course of action in case of ACE\u2010induced cough is substitution of the ACEi with other antihypertensive agents.<\/jats:p><jats:p>\u2022\u2003Misdiagnosis and mistreatment of ACEi\u2010induced cough has not been studied before.<\/jats:p><jats:p> <jats:bold>WHAT THIS STUDY ADDS<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003In the general population, a significant and clinically relevant proportion of patients with ACE\u2010induced cough are treated with antitussive agents.<\/jats:p><jats:p>\u2022\u2003These results suggest misdiagnosis and mistreatment of a well\u2010known side\u2010effect.<\/jats:p><jats:p>\u2022\u2003The estimated frequency of antitussive treatment of ACEi\u2010induced cough is 15%.<\/jats:p><\/jats:sec><jats:sec><jats:title>AIMS<\/jats:title><jats:p>Angiotensin\u2010converting enzyme inhibitors (ACEi) are frequently prescribed for various cardiovascular and renal diseases. A common side\u2010effect of these drugs is a persistent dry cough. Physicians who fail to recognize a dry cough to be ACEi\u2010related may attempt to treat it with antitussive agents instead of recommended ACEi substitution. Prescription behaviour in the general population considering treatment of the side\u2010effect with antitussive agents has not been studied before.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Drug dispensing data between 2000 and 2007 were retrieved from the IADB.nl database. A prescription sequence symmetry analysis was used to determine whether antitussive agents were prescribed more often following ACEi initiation than the other way around. A logistic regression model was fitted to determine predictors.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>We identified 27\u2003446 incident users of ACEi therapy. One thousand and fifty\u2010four patients were incident users of both ACEi and antitussives within a half\u2010year time span. There was an excess of patients being prescribed antitussive agents after ACEi initiation (703 <jats:italic>vs.<\/jats:italic> 351), adjusted sequence ratio 2.2 [confidence interval (CI) 1.9, 2.4]. Female patients were more likely to be prescribed antitussive agents following ACEi therapy initiation, odds ratio 1.4 (CI 1.1, 1.9), age and co\u2010medications were not significant predictors.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>There was a significant and clinically relevant excess of patients receiving antitussives after ACEi initiation. The results suggest that cough as a side\u2010effect of ACEi is not recognized as being ACEi\u2010related or is symptomatically treated with antitussive agents instead of ACEi substitution. The estimated frequency of antitussive treatment of ACEi\u2010induced dry cough is 15%.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2009.03571.x","type":"journal-article","created":{"date-parts":[[2009,10,23]],"date-time":"2009-10-23T09:20:03Z","timestamp":1256289603000},"page":"200-203","source":"Crossref","is-referenced-by-count":45,"title":["Misdiagnosis and mistreatment of a common side\u2010effect \u2013 angiotensin\u2010converting enzyme inhibitor\u2010induced cough"],"prefix":"10.1111","volume":"69","author":[{"given":"Stefan","family":"Vegter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lolkje T. W.","family":"De Jong\u2010van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,1,21]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp103"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042167"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)11445-8"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)10363-X"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-3-234"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199615010-00006"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1989.00390120061012"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/7.11.1012"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.10.901"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60596-6"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.129.1_suppl.169S"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archfami.4.6.525"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.2.976"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-10-200405180-00009"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7115.1096"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.882"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/3-540-39949-6_25"},{"key":"e_1_2_7_19_2","first-page":"347","volume-title":"Pharmacoepidemiology","author":"Leufkens HGM","year":"2008"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199609000-00005"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1736"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2009.03571.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2009.03571.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T21:02:38Z","timestamp":1697403758000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2009.03571.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,21]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["10.1111\/j.1365-2125.2009.03571.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03571.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,21]]}}}